Alerts

A session is dedicated to the Microbiota analysis 2016: The challenge of big data interpretation

The Scientific Committee decided to organize a special session about Microbiota analysis 2016: The challenge of big data interpretation.

Read more...

Skin microbiota: Towards a new era in dermocosmetics/ Dermatology

This review was based on symposium on skin microbiota which was organized by the International Society of Microbiota on June 17, 2015, Paris, France. Marvin Edeas, Chairman of the Scientific Committee of ISM stated: "This review shortly characterises skin microbiota and their functions. The impact of external factors such as xenobiotics, traumatization, UVB light, cosmetic products and antiseptics are discussed. Strategies to target axillary microbiota to prevent body odour, as well as potential targets to manipulate microbiota in cosmetics and athopic dermatitis are outlined with examples. In future we may expect that knowledge of skin microbionome will allow development of wide range of cosmetical products and stratify patient and people with high predispostion to disease subsets, predict the best treatment or preventiv modality and outcome and introduce new treatment strategies by targetely manipulation of microbial communities."

To access to this review, please contact ISM.

Targeting Microbiota Abstract Submission

Deadline for Short Oral Presentation Abstract Submission:
September 16, 2024

Deadline for Poster Presentation Abstract Submission:
September 19, 2024

Submission Guidelines:

1. Submit abstracts to the Scientific Committee.
2. Use the online form for submissions. Abstracts not using this form will not be considered.
3. One abstract per registered person.
4. For oral submissions: prioritize in-person presentations. Online presentations require prior approval.
5. Online poster submissions are accepted.
6. No changes after the submission deadline.
7. Abstracts cannot be modified post-acceptance.

Abstract Format:

1. Title: Max 20 words.
2. Text: Max 200 words, divided into Introduction, Materials & Methods, Conclusion.
3. Define unusual abbreviations on first use.
4. Relate to conference tracks or sessions, and specify the topic.
5. Include references (max 3).
6. Submit in both Word and PDF formats, prepared in B5 format.

Download abstract format guidelines here in Word or in PDF.

Abstracts not following the formalities will not be considered.

 Reviewing and Selection Process

• All submissions reviewed by the Scientific Committee.
• Selection based on originality, novelty, impact (score 1-10).
• Scores 9-10: considered for oral presentation.
• Scores 6-8: accepted for poster presentation.
• Preference for in-person short oral presentations.
• E-posters can be accepted.
• Low-quality or off-topic abstracts may be rejected.

Published Abstracts

Accepted abstracts will be published in the conference abstracts book.

Short Oral Presentations

• Duration: 8 minutes presentation, 2 minutes Q&A.
• Slide limit: 8 slides (+1 for title).
• Cover research aim, methods, results, conclusion.
• Timing subject to final program adjustments.

 Posters Session

• Format: A1 vertical (84.1cm x 59.4cm).
• Presented during coffee and lunch breaks.
• E-posters to be emailed to: microbiota[at]microbiota-ism.com

The ISM awarded Pr Iradj Sobhani for his Scientific Contribution during the 3rd World Congress on Targeting Microbiota

During the 3rd World Congress on Targeting Microbiota held at Pasteur Institute from October 21 to 23, Pr Iradj Sobhani from Hôpital Universitaire Henri Mondor, France gave a strategic presentation about "Cancer & Microbiota: Potential of fecal microbiota for early-stage detection of colorectal cancer".

According Pr Sobhani: "Colorectal cancer (CRC) is one of the main major problems in health care. The incidence is growing in western countries and no evident cause is found although germline DNA mutations in less than 5% of patients are identified and environment factors such as food, style of life, medicine, etc... are now suspected to induce majority of cancers. Exhaustive quantitative and qualitative evaluation of all factors from the environment is not possible. The microbiota may be considered as platform offering host and environment interactions for studying CRCs. And growing data show specific changes in microflora (dysbiosis) in colon cancer patients’ stools or adherent to the colonic mucosa. The hypothesis that colon cancer might be a bacteria-related disease is suggested and perspectives discussed."

The Scientific Committee of the International Society of Microbiota was delighted to award Pr Sobhani for this strategic presentation and his scientific contribution during the international congress.

For more information about the congress: www.microbiota-site.com

ISM is pleased to award three scientists for their oral and poster presentations

The Scientific Committee of the International Society of Microbiota awarded three scientists for their presentations during Targeting Microbiota World Congress which was held in Institut Pasteur, Paris:

- Dr Atti-La Dahlgren, Sweden for her short oral presentation about "Anaerobically Cultivated Human Intestinal Microbiota"

- Dr Heenam Stanley Kim, from Korea for his poster about "Subspecies-level dysbiosis of Faecalibacterium prausnitzii in the human gut microbiome underlies atopic dermatitis"

- Dr Erica Castro de Lourdes, Columbia, for her poster about "Selection of lactic acid bacteria for the prevention of dental caries"

If you would like to access to the abstracts of these three presentations, you can order the abstracts book by clicking here.

For more information about Targeting Microbiota 2015: www.microbiota-site.com

Dr Gurumoorthy Krishnamoorthy was awarded by the Scientific Committee of ISM for his Scientific Contribution

It is an honor to announce the award discerned by The Scientific Committee of ISM to Dr Gurumoorthy Krishnamoorthy from Max Planck Institute of Neurobiology, Germany for his scientific contribution about "The gut-brain axis in the CNS autoimmunity", during Targeting Microbiota 2014.

Read more...

Dr Atti-La Dahlgren was awarded for his presentation about Anaerobically cultivated human intestinal microbiota

Dr. Dahlgren is a Swedish physician specialised in International Public Health and is affiliated to Karolinska Institutet Department of Microbiology, Tumor and Cell biology, in Stockholm Sweden. His current field of research is the clinical application of Anaerobically Cultivated Intestinal Microbiota, especially in Recurrent Clostridium difficile infections, a major public health concern in US, Canada, Europe and other countries. Since 2003 he in an advisor to the Bhutan Health Trust Fund and the Ministry of Health in the Kingdom of Bhutan.

During Targeting Microbiota World Congress 2005, Dr Dahlgren gave a short oral presentation about "anaerobically cultivated human intestinal microbiota". 

For almost 20 years, Dr Dahlgren's team have produced a human intestinal microbiota under strict anaerobic conditions, as an in vitro batch culture. This cultivated microbial ecosystem designated anaerobic cultivated human intestinal microbiota (ACHIM) has been reinoculated every second week during the years into new production batches. The cultivated microbiota has retained a microbial diversity comparable to that of feces from healthy donors, containing the major bacterial phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria, as confirmed by gene sequencing.This batch-cultured microbial ecosystem has been tested for safety and clinical efficacy for many years in more than 400 patients, most of them suffering from recurrent Clostridium difficile-infection (RCDI). [...] 

The scientific committee was honoured to award Dr Dahlgren for this strategic study.

If you would like to access to the complete abstract, and to the complete abstracts book, you can order it by clicking here.

Targeting Microbiota Congress Great moments in Picture

Targeting Microbiota World congress was a exciting moment, where speakers and participants shared scientific knowledge in Microbiota.

You can find here some pictures of this three-days congress.

Read more...

The Scientific Committee published the final agenda of Targeting Microbiota World Congress

The Scientific Committee of the International Society of Microbiota published the Final agenda of Targeting Microbiota World Congress.

To access to the final program, please follow this link.

For all information about the congress: www.microbiota-site.com

The Subltle Balance Between Body Fat, Gut Microbiota and the Brain

John-Olov Jansson, of the Sahlgrenska Academy at Gothenburg University, Sweden will be discussing the subtle balance between body fat, gut microbiota and the brain at the 3rd World Congress on Targeting Microbiota, being held between the 21st and 23rd October at the Institut Pasteur, Paris.

The gut microbiota is a complex community including the life forms bacteria and archaea, but dominated by bacteria mainly from the phyla Firmicutes and Bacteroidetes. The effect of gut microbiota on host physiology is not limited to the gastrointestinal tract. Emerging evidence suggest that gut microbiota could influence the central nervous system (CNS). New insight suggests that gut microbiota are an integral component regulation of  energy balance, and that it can be regarded as an organ   that contributes to efficient energy metabolism. The germ free mouse, that completely lacks gut microbiota, is a common model to study the interplay between gut microbiota and metabolism. Total lack of microbiota is a non-physiological condition, and it is nonspecific in its nature. However, it is has proven to be a good model for understanding the most constitutive functions of gut microbiota. In addition, data from alternative models such as probiotic- or antibiotic treatment could be problematic to interpret due to the immense complexity of gut microbiota, as well as our so far unsatisfactory knowledge of its constituents and their interrelations. Data from germfree mice are in line with interactions between  gut microbiota and  neuropeptides such as glucagon-like peptide (GLP-1) and brain derived growth factor (BDNF) in  parts of the brain regulating body fat mass. Further studies are needed to evaluate the biological significance of these findings.

Dr Jansson will present more details and strategies during IMS' Pasteur meeting.

For more information, please visit www.microbiota-site.com/

To Swab or Not to Swab? Rectal Swabs for Intestinal Microbiota Analysis

Ms Anat Eck of the VU Medical Center in the Netherlands will be discussing Rectal Swabs for Intestinal Microbiota at the 3rd World Congress on Targeting Microbiota, being held between the 21st and 23rd October at the Institut Pasteur, Paris.

The composition of the gut microbiota is associated with various disease states, most notably inflammatory bowel disease, obesity and malnutrition. This underlines that analysis of intestinal microbiota is potentially an interesting target for clinical diagnostics. However, since sampling method, storage and processing of samples impact microbiota analysis, it is important to define standards for reproducible and accurate sampling of gut microbiota that can be implemented in clinical routine. 

Ms Eck will present more details and strategies during IMS' Pasteur meeting.

For more information, please visit www.microbiota-site.com/

Who will attend Targeting Microbiota World Congress 2015 from Industries & Academics?

Targeting Microbiota 2015 will gather academics and industrial leaders in the field of microbiota research.

Among the participants:

Libragen, Genoscreen, Vaiomer, MO BIO, Biocodex, Synthetic Biologics, L'Oréal, Cosmetic Active International, Merial, Laboratoires Clarins, Provital, Evonik Nutrition, AF Consulting, Genetic-Analysis, IPSEN Pharma, Lallemand Health Solutions, Qiagen, Morinaga Milk Industry, Cosmetique Active International, Merial, Laboratoires Clarins Lonza, Dr Pierre Ricaud-Groupe Rocher, BASF Personal Care & Nutrition Provital, L'Oréal Innovation & Research, BASF Beauty Care Solutions Probionov, Merck Kgaa, Pierre Fabre Dermo-Cosmétique, Nutriset Bondonno Natural Health, Bioaster, Nestle Institute of Health Sciences Roquette Freres, Procter & Gamble,Abbio Alma Bio Therapeutics, Rebiotix, Biofortis Seventure Partners, Capsugel

Paris Descartes Unviersity, University of Toyama, University Hospital of Liège, Utah State University, Dept of Thoracic Medicine, Haukeland, University Hospital, CHU de Nice, University of Gothenburg, University of Coimbra, Istituto Italiano Di Tecnologia, Fundación Rioja Salud, Karolinska Institutet, Karolinska Institutet, University Of São Paulo, Paris 13 University, Pontificia Universidad Catolica de Chile, University of Pavia, University of Manchester, The Center for Restorative Medicine, APC Microbiome Institute, University College Cork, Labmet - Ghent University, Department of Public Health and Infectious Diseases, ‘Sapienza’ University of Rome Fondazione Centro San Raffaele, National Institutes of Health/NCI, INSERM, Université d'Auvergne University of Helsinki, CNRS, University of Leipzig, University of Southern Denmark, Shumway Capital Barretos Cancer Hospital - Pio XII Foundation, Hong Kong Baptist University, ACT Health/Australian National University Fondazione IRCCS Istituto Nazionale Dei Tumori, Korea University, University of Turku, University of Zagreb Vanderbilt University, Case Western Reserve University, Chungnam National University, Umeå University Newcastle University, University of British Columbia, Clemson University, Centre for Obesity Research and Innovation, St. Olavs Hospital, INRA / MICALIS University of Frankfurt/Main, University of Sydney, Alimentary Pharmabiotic Centre, University College Cork, UC Davis Texas A&M University, Clinique de Pédiatrie du Saguenay, University of Western Australia,University of Oslo, University of California Davis Sri Ramachandra University, Medical University of Warsaw, Pisa University, Norwegian Veterinary Institute, University of Nebraska-Lincoln, University of Michigan, Hospital Sant Joan De Déu, Vilnius University Hospital Ewha Womans University, Tohoku University, Tehran University of Medical Sciences, Istituto Auxologico Italiano School of Health Sciences Paulo Prata, City of Hope, Korea Research Institute of Bioscience and Biotechnology University Medical Center Hamburg Eppendorf, University of Calgary, Marmara University CSM, King's College London, University of Stavanger, University College Cork Kasetsart University, University of Tartu, Faculté Médecine Marseille, CIDAM, Imgge University of Belgrade, Riga Stradins University...

If you would like to register and join all these leaders in microbiota field: www.microbiota-site.com

The Interactions Between the Host, the Vaginal Microbiota and Sexually Transmitted Infections: A hot topic of Targeting Microbiota 2015

Pr Jacques Ravel will be present at the 3rd World Congress on targeting Microbiota and talk about "The interactions between the host, the vaginal microbiota and sexually transmitted infections"
Pr Ravel is the Associate Director for Genomics at the Institute for Genome Sciences (IGS) and a Professor of Microbiology and Immunology at the University of Maryland School of Medicine in Baltimore, Maryland.


Pr. Ravel’s research program focuses on applying modern genomics technologies and ecological principles to characterize the role and dynamics of the microbial communities inhabiting the human body in health and disease and better define the interactions between the host, the microbes and the environment that drive these ecological systems. Specifically, he is interested in deciphering the role of the vaginal microbiome in women's health using clinical genomics and systems biology approaches, in order to develop improved strategy to manage gynecological and obstetrics conditions. He is the co-Directors of the NIH funded Collaborative Research Center on Sexually Transmitted Diseases entitled Ecopathogenomics of Sexually Transmitted Diseases (EPSTI – epsti.org) which aims at applying systems biology approaches to examine the triangular relationship between human genetic variation, sexually transmitted infections and co-infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae, and the function of the vaginal microbiome.

He is a fellow of the American Academy of Microbiology. Dr. Ravel is the Editor in Chief of the journal Microbiome and an Associated Editor for the journal mBio.

If you would like to know more about Pr Jacques Ravel's study results, don't hesitate and come along to the conference.

For more information: www.microbiota-site.com

Listeria monocytogenes will be introduced by Dr Javier Pizzaro Cerda from Pasteur Institute

Dr Javier Pizarro Cerda, from Pasteur Institute will share his research about 'Modulation of Host Microbiota by Listeria monocytogenes' during the 3^rd World Congress on Targeting Microbiota, held in Pasteur Institute (Paris, France).

According to him, "listeria monocytogenes is a foodborne bacterial pathogen which can induce gastroenteritis, abortions in pregnant women and meningitis in the new born. Epidemic Listeria monocytogenes strains are characterized by the presence of a pathogenicity island coding for the toxic peptide listeriolysin S (Lls). Lls has been previously described as a virulence factor required for bacterial survival within animal hosts; our recent work demonstrates that Lls is the first described Listeria monocytogenes bacteriocin which modulates the host intestinal microbiota, favoring bacterial colonization of the intestine and allowing bacterial dispersal to other host organs".

If you would like to know more about that specific topic and others, don't hesitate and come.

For more information: www.microbiota-site.com

Pr Ernst Holler will present his researches about Metagenomic analysis of microbiota during Targeting Microbiota 2015

During the 3rd World Congress on Targeting Microbiota 2015 scheduled on October 21-23, 2015 at Institut Pasteur, Paris, the Scientific Committee is pleased to welcoming Pr Holler, from the University Medical Center Regensburg in Germany.

Pr Holler who will give a talk about Metagenomic Analysis of the microbiota in patients receiving allogeneic SCT: Role of harmful versus protective microbiota and the impact of antibiotic prophylaxis and treatment.

Pr Holler from the University Medical Center Regensburg in Germany will present his work concerning the role of intestinal microbiota in allogeneic stem cell transplantation.

If you would like to know more about Pr Holler's study, don't hesitate and come.

For more information: www.microbiota-site.com

HIV infection & microbiota diversity and quality: how HIV modify gut microbiota?

Gut microbiota modifications occurring during HIV infection have recently been associated with inflammation and microbial translocation. However, discrepancies between studies justified a comprehensive analysis performed on a large cohort.

During his presentation, during Grégory Dubourg, from University of Marseille, France will discuss about HIV and Microbiota. According Dr Dubourg "Next-generation sequencing of the 16S rRNA gene was applied to the faecal microbiota of 31 HIV-infected patients and compared to healthy controls. Sera were used to test the presence of 25 markers of inflammation and/or immune activation. Diversity was significantly reduced in HIV individuals when compared to the controls and was not restored by ART.  [...]

If you would like to know more about HIV and microbiota, you have to register on www.microbiota-site.com

Gut microbiota: novel & strategic players in coeliac disease pathogenesis

During Targeting Microbiota World Congress, Pr Elena Verdu from McMaster University, Canada will present the novel & strategic players in coeliac disease pathogenesis.

According to Pr Verdu: "Disruption to the microbiota in early-life has been implicated in celiac disease pathogenesis. Early antibiotic use has been associated with the emergence of celiac disease. Some studies indicate that delivery mode is also influential in the development of this disease, although not all studies support this link. Infants at high risk of developing celiac disease exhibit dysbiosis, where the Bacteroidetes:Firmicutes ratio is decreased, B. fragilis and Staphylococcus spp. are increased, and less B. longum and Bifidobacterium spp. are present. The studies indicate a potential association but there is currently no evidence or described mechanisms for alterations in the microbiota to modulate celiac disease risk."

If you would like to know more about Gut microbiota: novel & strategic players in coeliac disease pathogenesis, you can register by following this link.

For more information: www.microbiota-site.com

Microbiota & Horses: Towards a revolution on animal medicine

All you need to know to sequence microbiota in horses will be discussed during Targeting Microbiota World Congress 2015.

During the workshop of the congress, a special session is dedicated to What we can learn from microbiota analysis and how to apply this to animal health?

The scientifc committee of ISM invited Dr Knut Rudi from Norway University of Life Sciences to give a presentation about Dynamic interactions of the equine hindgut microbiota in health and disease.

According Dr Rudi: "Horses derive 60-70 % of their energy through microbial hindgut fermentation. The fermentation is a delicate dynamic process where energy overload and can lead to a severe diseased acidotic state. Based on microbiome data we have developed dynamic models to both understand the diseased - and non-diseased microbiota. These models revealed the importance of short-term (within hours) dynamic interactions. We believe that dynamic modelling also can be a valuable contribution for understanding the role of the microbiota in health and disease for other organisms."

To know more about Microbiota sequencing, don't hesitate to register to the workshop on www.microbiota-site.com

Pancreatic beta-cells limit autoimmune diabetes: strategic role of gut microbiota

Antimicrobial peptides expressed by epithelial cells are largely described for the defense against pathogens but how they influence autoimmunity in peripheral tissues was unknown. Dr Julien Diana, from INSERM and Descartes University, France, and his team show that the cathelicidin related antimicrobial peptide CRAMP is expressed by the pancreatic endocrine cells. Owing to its immunoregulatory capacities, CRAMP is protective against autoimmune diabetes in NOD mice, a model for type 1 diabetes. They finally demonstrate that the gut microbiota via short-chain fatty acids directly governs the expression of CRAMP in the pancreas revealing the direct role of the gut microbiota in the maintenance of the immune homeostasis in peripheral tissues.

Dr Diana will present this study during the next Targeting Microbiota World Congress which will be held at Pasteur Institute on October 21-23.

For more information: www.microbiota-site.com

What is the role of gut microbiota in Parkinson’s disease?

This question will be answered by Dr Filip Scheperjans from Helsinki University Central Hospital, Finland during the 3rd World Congress on Targeting Microbiota which will be held at Pasteur Institute on October 21-23, 2015. 

Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting approximately 1% of the population over 60 years of age. In addition to the classical motor symptoms of the disease, patients suffer from a broad spectrum of non-motor symptoms. About 80% of patients have gastrointestinal dysfunction, most frequently constipation, and these frequently precede the onset of motor symptoms by years. This is associated with neurodegeneration in the enteric nervous system. Recent research suggests that the gastrointestinal tract is actually the first structure to show neurodegeneration in PD and that this degenerative process may subsequently spread to the brainstem via the vagal nerve. Alterations of gut physiology, mucosal permeability, inflammation, and most recently gut microbiome composition have been reported in PD patients and may be relevant for the pathogenesis of the disease. The talk will give an overview of gut pathophysiology in PD and address the possible role of gut microbiota in this context. 

To know more about Targeting Microbiota World Congress: www.microbiota-site.com